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Targeted Online Liquid Chromatography Electron
Capture Dissociation Mass Spectrometry for the
Localization of Sites of in Vivo Phosphorylation in
Human Sprouty2
Steve M. M. Sweet,† Faraz K. Mardakheh,† Kevin J. P. Ryan,† Amy J. Langton,† John K. Heath,†
and Helen J. Cooper*
School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.
We demonstrate a strategy employing collision-induced
dissociation for phosphopeptide discovery, followed by
targeted electron capture dissociation (ECD) for site
localization. The high mass accuracy and low background
noise of the ECD mass spectra allow facile sequencing of
coeluting isobaric phosphopeptides, with up to two iso-
baric phosphopeptides sequenced from a single mass
spectrum. In contrast to the previously described neutral
loss dependent ECD method, targeted ECD allows analy-
sis of both phosphotyrosine peptides and lower abun-
dance phosphopeptides. The approach was applied to
phosphorylation analysis of human Sprouty2, a regulator
of receptor tyrosine kinase signaling. Fifteen sites of
phosphorylation were identified, 11 of which are novel.
Phosphorylation is a widespread and biologically significant
protein post-translational modification.1 Phosphopeptide discovery
is becoming more routine, thanks largely to improved enrichment
methods and higher speed mass spectrometers.2,3 However site
localization from collision-induced dissociation (CID) mass spectra
remains a challenge, particularly for larger phosphopeptides with
multiple potential phosphorylation sites.4 Low-energy CID frag-
mentation of phosphopeptides frequently results in losses of
phosphoric acid, in addition to the typical CID losses of water
and ammonia, thus complicating manual analysis.5-7 Bioinformatic
approaches to automation of site localization have recently been
published.8,9 While automation streamlines the localization pro-
cess, many CID spectra still give ambiguous results, e.g., 39 and
33% of sites in two recent large-scale studies where confidence of
site localization was quantified.8,10 Site-directed mutagenesis is
commonly used in order to decipher the functional significance
of phosphorylation for a given protein.11 If site-directed mutagen-
esis is to be carried out, obtaining accurate localization data for
as many sites of phosphorylation as possible is particularly
important, in order to avoid lengthy and costly analysis of
inappropriate residues.
Alternative mass spectrometric methods for site localization
include MS3 of the H3PO4 neutral loss product ion, negative mode
CID, and non-CID radical-driven fragmentation. Neutral loss
dependent MS3 spectra have been used to increase confidence
in phosphopeptide identifications;9,12-14 however, their contribu-
tion to site localization has not been rigorously described. Jiang
et al. used information from paired MS2 and MS3 spectra to
localize the site of phosphorylation, but neither the relative
contributions to localization from the different scan types nor the
confidence of site localization was reported.12 Beausoleil et al.
found that MS3 spectra provided little additional localization
information, an observation that was ascribed to reduced ion
statistics in MS3 spectra.8 An additional caveat is that the neutral
loss of water from unmodified residues results in a fragment of
the same mass as loss of H3PO4 from a phosphorylated residue.7,15
The use of negative ion mode CID to differentiate between clusters
of potential phosphorylation sites has been described.4 This
method is based on a difference in intensity between two
fragments, rather than distinct fragments.
Electron capture dissociation (ECD) and electron-transfer
dissociation (ETD) are radical-driven fragmentation techniques.16,17
In contrast to CID, labile modifications such as phosphorylation
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are retained on peptide backbone fragments upon ECD/ETD
fragmentation.18-21 This feature of ECD/ETD gives these meth-
ods a significant advantage over CID for the localization of
phosphorylation sites.21 ETD has recently been applied to the
identification of large numbers of phosphopeptides in proteomic
experiments.22,23 ETD is performed predominantly on low-resolu-
tion ion trap mass spectrometers, and ambiguities arise from the
possibility of fragment ions of the same nominal mass. Work is
ongoing to implement ETD on an instrument with a high-
resolution mass analyzer.24,25 ECD has the advantage that mass
spectra are acquired with high resolution and mass accuracy, as
it is virtually exclusive to Fourier transform ion cyclotron
resonance mass spectrometry. We have shown previously that
online liquid chromatography (LC) ECD can be used in phos-
phopeptide discovery.26 That method, neutral loss dependent ECD
(NL ECD), takes advantage of the signature neutral loss of H3PO4
in order to focus ECD time on phosphopeptides. ECD has the
potential to give excellent quality mass spectra of phosphopeptides,
but it is unlikely to be as efficient as CID for phosphopeptide
discovery, due to the requirement for accumulation of considerably
greater amounts of precursor with concomitant increases in scan
time.
In order to maximize the advantages of ECD, we now present
an alternative application of ECD for site localization. Phospho-
peptide discovery is carried out in an initial LC-CID experiment,
followed by targeted LC-ECD of the identified phosphopeptides,
enabling site localization and confirmation of the phosphopeptide
identification. The use of an initial stage of mass spectrometry to
generate an inclusion list for subsequent analysis has been applied
previously to the identification of phosphopeptides and other
substoichiometric components of a mixture.27,28 Annan et al.
employed negative ion mode precursor ion scanning, followed by
positive ion mode MS/MS analysis of the resulting precursor
ions.28 Picotti et al. employed multiple rounds of targeted LC-CID
MS/MS in order to identify low-abundance components of a
protein digest.27 In our targeted LC-ECD method, ECD analyses
are not dependent on the presence of a CID neutral loss peak,
allowing site localization of phosphotyrosine peptides (which do
not show a dominant neutral loss). ECD events are restricted to
a known number of phosphopeptides, allowing the ECD time to
be extended to improve sequencing of low-abundance phospho-
peptides: The least abundant phosphopeptide identified had a 200-
fold lower intensity than the most abundant phosphopeptide. We
apply this strategy to human Sprouty2, an important regulator of
receptor tyrosine kinase signaling.29 Sprouty2 has been shown
to antagonize pathways downstream of fibroblast growth factor
signaling.29,30 Tyrosine phosphorylation (at Tyr55) has been
shown to be essential for this antagonism; however, the mecha-
nism by which this is accomplished is largely unknown.29,31
Sprouty2 is downregulated in various cancers, suggesting it has
a tumor-suppressor role.32 In addition to tyrosine phosphorylation,
Sprouty2 is known to be phosphorylated on serine and threonine
residues.30,33 Alterations in Sprouty2 phosphorylation, observed
as a shift in SDS PAGE migration, have been implicated in
Sprouty2 activity.33-35 Precise localization of the sites of Sprouty2
phosphorylation will allow the role of phosphorylation in Sprouty2
function to be assessed further.
By use of targeted ECD, we were able to identify 14 sites of
phosphorylation, 11 of which have not been described previously.
Taking advantage of the high mass accuracy and low background
noise levels of the ECD spectra, we demonstrate that up to two
coeluting isobaric phosphopeptides can be assigned from a single
ECD spectrum. ECD has been widely hailed as applicable to the
analysis of phosphorylation.20,21,36 While ECD has been applied
to the identification of known sites of phosphorylation and to the
identification of sites of phosphorylation on synthetic pep-
tides,21,36-38 this work is among the first applications of ECD to
the assignment of novel sites of in vivo phosphorylation on a
biologically significant signaling protein.39,40
EXPERIMENTAL METHODS
Plasmid Constructs. N-Terminally tagged Myc-human Sprouty2
(hSpry2) was constructed via Gateway cloning (Invitrogen Life
Technologies).Briefly,thepreviouslydescribedhSpry2(WT)spEFBOS-
ires-Topaz construct was used as template,41 along with the
following Gateway compatible forward and reverse primers:
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( G G G G A C A A G T T T G T A C A A A A A A G C A G G C T -
TGATGGAGGCCAGAGCTCAGAGTG, and GGGGACCACTTTG-
TACAAGAAAGCTGGGTCCTATGTTGGTTTTTCAAAGTTC) in a
PCR to synthesize a hSpry2 coding fragment with in-frame
gateway sequence overhangs. The product was subsequently
recombined into GatewaypDONR201 entry vector (Invitrogen),
using BP clonase enzyme (Invitrogen). Myc tagged hSpry2 was
then generated by recombining hSpry2 from pDONR201 entry
vector into a Myc-pRK5 gateway mammalian expression vector
(kindly provided by Laura M. Machesky, University of Birming-
ham), using LR clonase enzyme (Invitrogen).
Reagents and Antibodies. Mouse monoclonal anti-c-Myc
(clone 9E10) antibody was provided from Cancer Research UK
(CRUK) Research Monoclonal Antibody Service. Horseradish
peroxidase conjugated secondary anti- mouse IgG antibodies were
purchased from Amersham Biosciences Inc. Protein-G coupled
Sepharose beads were purchased from Sigma Aldrich (Gillingham,
Dorset, UK). TiO2 Titansphere beads (5-µm diameter) were
obtained from GL Sciences (Japan).
Cell Culture, Transient Transfection, and Immunopre-
cipitation. Human embryonic kidney epithelial 293T cells were
cultured at 37 °C, 5% CO2 in Dulbeccos Modified Eagle Medium
(Invitrogen) supplemented with 10% fetal bovine serum (v/v)
(Labtech International). Transfections were performed using
GeneJuice transfection reagent (Novagen) according to the
manufacturer’s instructions. Cells were incubated for 36 h after
transfection to allow sufficient expression of the recombinant
proteins. The efficiency of transfection was monitored using a GFP
transfected positive control and was at all times >50%. Following
transfections, cells were lysed with ∼3 µL of ice-cold lysis buffer/
cm2 of confluent cells (50 mM Tris pH 7.5, 1 mM EDTA pH 7.5,
150 mMNaCl, 0.5% TritonX-100 (v/v), 1 mMNa3VO4, 50 mMNaF,
1 mM phenylmethanesulfonyl fluoride, and 1 tablet of complete
mini protease inhibitor cocktail (Roche Diagnostics) for every 10
mL of buffer) Lysates were subsequently cleared by centrifugation
at 14000g for 20 min. All steps were performed at 4 °C. Total
protein concentrations of the cleared lysates were then determined
by Coomassie (Bradford) Protein Assay Kit (Pierce Biotechnology
Table 1. Sprouty2 Phosphopeptides Identified from Initial LC-CID MS/MSa
phosphopeptideb site
number of
potential sites precursor m/z (charge state)
precursor mass
accuracy (ppm)
Mascot
Expect valuec
Site localized?
(Ascore)d
R.AQpSGN*GSQPLLQTPR.D Ser 7 3 817.88(2) 1.5 0.0012 yes (66.7)
R.DALTQQVHVLpSLDQIR.A Ser 42 2 958.49(2) 0.9 6.6 × 10-4 yes (127.5)
R.NTNEYpTEGPTVVPR.P Thr 56 4 828.87(2) 7.6 34† no (0)
R.SISTVSpSGSR.S Ser 116 6 530.74(2) 7.0 0.14† no (7.93)
R.LLGSSFpSSGPVADGIIR.V Ser 141 4 878.44(2) 0.4 7.6 × 10-7 no (16.2)
K.SELKPGELKPLpSK.E Ser 167 2 753.40(2) 3.8 0.0062 yes (89.8)
K.VPpTVPPR.N Thr 305 1 423.22(2) 0.9 0.018 yes (n/a)
a Mascot scores were above the threshold for identity or extensive homology, except where indicated as †. (Identification was confirmed by
subsequent ECD fragmentation). b Lowercase p indicates phosphorylation throughout. * indicates deamidation. c Mascot Expect value indicates
the number of times a random equal or higher score could be expected (p > 0.05). d Ascore algorithm was used to assess site localization: Ascore
g20 indicates confident localization (p ) 0.01).8
Figure 1. Online nanoLC separation of Sprouty2 tryptic digest, after phosphopeptide enrichment, with data-dependent CID of phosphorylated
NTNEY55TEGPTVVPR. (a) Extracted ion chromatogram, showing elution of phosphorylated NTNEY55TEGPTVVPR, as [M + 2H]2+ ions. The
arrow marks the selection of these precursor ions for CID. (b) CID fragmentation of [M + 2H]2+ ions of phosphorylated NTNEY55TEGPTVVPR.
Lowercase p indicates phosphorylation. Inset: observed backbone fragments.
6652 Analytical Chemistry, Vol. 80, No. 17, September 1, 2008
Inc.), according to the manufacturer’s instructions. For immuno-
precipitation, ∼50 µg of anti-Myc antibody was directly added to
∼7 mg of lysate and incubated for 6 h at 4 °C with gentle agitation,
followed by addition of 100 µL of 50% washed protein G-Sepharose
fast flow slurry (Amersham Biosciences Inc.). The mixture was
then further incubated for 16 h at 4 °C. After incubation, beads
were washed 5 times with ice-cold lysis buffer (20× the bed volume
of the beads), before being resuspended and boiled for 5 min in
2× SDS PAGE sample buffer (10% glycerol (v/v), 2% SDS (w/v),
0.1% bromophenol blue (w/v), 200 mM 1, 4-dithiothreitol (DTT),
100 mM Tris HCl, pH 6.8). Samples were then resolved on 4-12%
precast NuPAGENovex Bis-Tris gels (Invitrogen) using NuPAGE-
MOPS SDS Running Buffer (Invitrogen), and protein bands were
visualized by staining with ImperialProtein Coomassie stain
(Pierce Biotechnology Inc.) for 1 h.
In-Gel Digestion and Phosphopeptide Enrichment. Fol-
lowing Coomassie staining, the Sprouty2 band was excised.
Cysteines were reduced (10 mM DTT) and alkylated (50 mM
iodoacetamide) prior to overnight in-gel trypsin digestion (12.5
ng/µL; Trypsin Gold; Promega, Madison, WI) in 25 mM am-
monium bicarbonate.
Phosphopeptides were enriched from the resulting mixture by
TiO2 affinity chromatography according to Larsen et al.,2 with
minor modifications. Peptides were loaded onto TiO2 microcol-
umns in 2% trifluoroacetic acid (TFA). Columns were washed with
100 mg/mL 2,5-dihydroxybenzoic acid (DHB), 80% MeCN, 2%
TFA, then with the same buffer omitting DHB. Peptides were
eluted in a two-step procedure with 50 mM Na2HPO4 followed by
dilute NH4OH solution. Eluates were desalted using C18 ZipTips,
according to the manufacturer’s instructions (Millipore). The
resulting peptide mixtures were analyzed by liquid chromatog-
raphy tandem mass spectrometry (LC-MS/MS).
Liquid Chromatography Tandem Mass Spectrometry.
Online liquid chromatography was performed by use of a Micro
AS autosampler and Surveyor MS pump (Thermo Electron,
Bremen, Germany). Peptides were loaded onto a 75-µm (internal
diameter) Integrafrit (New Objective, USA) C842 resolving column
(length 10 cm) and separated over a 40-min gradient from 0 to
40% acetonitrile (Baker, Holland). Peptides eluted directly (∼350
nL/min) via a Triversa nanospray source (Advion Biosciences,
NY) into a 7-T LTQ FT mass spectrometer (Thermo Electron),
where they were subjected either to data-dependent CID or to
targeted ECD.
Data-Dependent Collision-Induced Dissociation. The mass
spectrometer alternated between a full FT-MS scan (m/z 395-1600)
and subsequent CID MS/MS scans of the five most abundant
ions. In the CID analysis of the phosphopeptide-enriched sample,
if a neutral loss of 98 Da (49 or 32.67 m/z) from the precursor
ion was observed in the five most abundant ions in the CID mass
spectrum, an MS/MS/MS scan of the neutral loss ion was also
acquired. Survey scans were acquired in the ICR cell with a
resolution of 100 000 at m/z 400. Precursor ions were isolated
and subjected to CID in the linear ion trap. The width of the
precursor isolation window was 3 m/z. Only multiply charged
precursor ions were selected for MS/MS. CID was performed
with helium gas at a collision energy normalized to precursorm/z
of 35%.43 Activation q was 0.25. Precursor ions were activated for
30 ms. Dynamic exclusion was used with a repeat count of 2 and
an exclusion duration of 120 s. Data acquisition was controlled
by Xcalibur 2.0 software.
(42) Chi, A.; Valencia, J. C.; Hu, Z.-Z.; Watabe, H.; Yamaguchi, H.; Mangini,
N. J.; Huang, H.; Canfield, V. A.; Cheng, K. C.; Yang, F.; Abe, R.; Yamagishi,
S.; Shabanowitz, J.; Hearing, V. J.; Wu, C.; Appella, E.; Hunt, D. F. J. Proteome
Res. 2006, 5, 3135–3144.
(43) Lopez, L. L.; Tiller, P. R.; Senko, M. W.; Schwartz, J. C. Rapid Commun.
Mass Spectrom. 1999, 13, 663–668.
Figure 2. Online nanoLC targeted ECD of [M + 2H]2+ ions of phosphorylated NTNEY55TEGPTVVPR. ECD mass spectra of [M + 2H]2+ ions
of phosphorylated NTNEY55TEGPTVVPR (a) at retention time 26.2 min and (b) at retention time 27.6 min. ECD mass spectra comprise 24
coadded microscans. Inset: observed backbone fragments.
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DTA files were created from the CID data using Bioworks
3.3.1 (Thermo Fisher Scientific Inc.) (parameters: no scan
grouping; minimum ion threshold of 15; absolute intensity
threshold of 50). The DTA files were searched against the
Swissprot database (version 54.4; 287 050 entries) using the
Mascot algorithm (Mascot version 2.2.03; http://www.matrix-
science.com/; Matrix Sciences, UK). The search parameters
used were as follows: human; fully tryptic (cleavage N-terminal
to proline allowed); three missed cleavages allowed; carbami-
domethylation as fixed modification; oxidation (M), deamidation
(NQ), and phosphorylation (STY) as variable modifications;
precursor accuracy of 50 ppm; fragment accuracy of 0.5 Da;
instrument type ESI-Trap. The taxonomy filter resulted in 17
565 protein sequences being considered in the database search.
Accepted identifications scored within the significance thresh-
old (p > 0.05), except where noted (see Table 1), and had less
than 10 ppm mass error. All CID identifications were confirmed
by subsequent ECD data. Phosphorylation site localization from
CID mass spectra was assessed using the A-score algorithm
(http://ascore.med.harvard.edu/),8 with manual validation.
Targeted Electron Capture Dissociation. The mass spec-
trometer acquired full FT-MS scans (m/z 395-1600) until the
appearance of ions on an inclusion list triggered sequential CID
and ECD MS/MS scans. Precursor ions were isolated in the ion
trap and transferred to the ICR cell for ECD. Isolation width was
6 m/z. Automated gain control was used to accumulate sufficient
precursor ions (target value 1e6, maximum fill time 1 s). The
electrons for ECD were produced by an indirectly heated barium
tungsten cylindrical dispenser cathode (5.1-mm diameter, 154 mm
from the cell, 1 mm off-axis). The current across the electrode
was ∼1.1 A. Ions were irradiated for 60 ms at 5% energy
(corresponding to a cathode potential of -2.775 V). Each ECD
scan comprised either 8 or 24 coadded microscans, acquired with
a resolution of 25 000 at m/z 400. Precursor ions for ECD
fragmentation with 8 microscans were selected from an inclusion
list containing the following m/z values: 423.22, 512.87, 530.74,
585.96, 639.33, 640.83, 666.32, 704.12, 817.39, 817.88, 828.87,
854.11, 878.44, 958.49. Precursors for fragmentation with 24
microscans were as above, with the omission of 423.22, 817.39,
and 817.88, in order to focus on the Tyr55 phosphopeptide. The
tolerance window for these parent ions was set at ±0.05 m/z.
Dynamic exclusion was used with a repeat count of two and an
exclusion duration of 30 s. ECD data were manually assigned,
based on the known peptide sequences from the initial CID
identifications.
RESULTS AND DISCUSSION
Human embryonic kidney cells were transfected with epitope-
tagged human Sprouty2. After immunoprecipitation and SDS
PAGE, the band corresponding to Sprouty2 was excised and
subjected to in-gel trypsin digestion. The resulting peptide mixture
was analyzed by standard LC-CIDMS/MS, either directly or after
phosphopeptide enrichment.2 The phosphopeptides identified
from these initial experiments are shown in Table 1. We have
applied the recently developed Ascore tool to assist in phospho-
peptide localization from CID mass spectra.8 The Ascore algorithm
is designed to automate the time-consuming process of manual
site localization and to give a probabilistic score of the confidence
in the localization. The Ascore is extremely useful, but we would
urge caution in accepting all localized sites (scores >20) without
manual analysis of the key differentiating fragment peaks, as ion
trap spectra have a reasonable level of background noise, which
may contribute to the localization score. Neutral loss dependent
Figure 3. Online nanoLC targeted ECD of [M + 2H]2+ ions of
phosphorylated LLGS138SFSSGPVADGIIR. (a) Extracted ion chro-
matogram, showing elution of phosphorylated LLGS138-
SFSSGPVADGIIR, as [M + 2H]2+ ions. The arrows mark the selection
of the precursor ions for ECD. ECD mass spectra of [M + 2H]2+ ions
of phosphorylated LLGS138SFSSGPVADGIIR at retention times (b)
36.5, (c) 37.7, and (d) 38.7 min. Insets show fragments observed
and expanded views of *z10 and *z13, indicating the presence of
phosphorylated Ser141 and Ser138, respectively. ECD mass spectra
comprise 24 coadded microscans.
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MS3 spectra were also acquired in the CID experiment after
phosphopeptide enrichment. MS3 spectra for four of the seven
phosphopeptides in Table 1 were obtained (data not shown);
however, interpretation of these spectra was complicated by the
potential for neutral loss of water from unmodified amino acids.
MS3 spectra were not used for phosphorylation site localization
in this work.
Fifteen proteins were identified from the Sprouty2 gel band,
in addition to Sprouty2, in the LC-CID MS/MS analysis without
phosphopeptide enrichment (data not shown). Coelution of pep-
tides similar in mass was observed in this experiment. Phospho-
peptide enrichment reduced the sample complexity, allowing clean
isolation of precursor ions. The enrichment step is particularly
important for the ECD analysis (see below) as a larger isolation
window (6 vs 3 m/z) is used to ensure sufficient ions are
transferred to the ICR cell. In the ideal case of a completely
purified small phosphoprotein, targeted site localization could be
carried out without phosphopeptide enrichment. In practice, partial
purification with additional phosphopeptide enrichment will often
be the more straightforward option.
The phosphopeptides identified contain a total of 22 potential
sites of phosphorylation. Putative site localization is shown in Table
1; however, for three out of seven peptides, the CID-based
localization is ambiguous. The phosphopeptide containing Tyr55
is of particular interest, as phosphorylation of Tyr55 has been
shown to be critical for Sprouty2 function.29 It should be noted
that the Tyr55-containing peptide in Table 1 is nontryptic, with
cleavage occurring between arginine and proline.44 A longer
version of this peptide was identified in the analysis without
enrichment, suggesting the acidic conditions of the phosphopep-
tide enrichment procedure may cause this fragmentation.45 The
CID mass spectrum of the Tyr55-containing peptide shows a
dominant neutral loss of H3PO4, suggesting that the phosphory-
lation is on a threonine (Thr52 or Thr56) rather than Tyr55
(Figure 1). Unambiguous localization of the site of phosphorylation
was not possible. Examination of the extracted ion chromatogram
suggested that two versions of the peptide were present (Figure
1a); however, only the later eluting of these was selected for CID
fragmentation.
In order to further examine the Tyr55-containing phospho-
peptide and to confirm the localization of the other identified sites
of phosphorylation, a targeted ECD analysis was carried out. The
immunoprecipitation and phosphopeptide enrichment was re-
peated, and an inclusion list of the identified phosphopeptides
(shown in Table 1) was used to restrict ECD events to the
precursors of interest. Two targeted ECD analyses were carried
out: one with 8 microscans per ECD spectrum and one with 24.
The longer ECD events gave higher quality spectra for some low-
abundance phosphopeptides, but results from both analyses were
in agreement. In these analyses, both the earlier- and later-eluting
Tyr55-containing phosphopeptide peaks were fragmented (Figure
2). The two mass spectra clearly show that the first-eluting peak
corresponds to phosphotyrosine 55 (Figure 2a) and the second-
eluting peak to phosphothreonine 56 (Figure 2b), a site of
phosphorylation that has not been described previously. As with
our previous NL ECD strategy,26 the approach taken here is
designed to maximize the advantages of ECD for phosphopeptide
identification, specifically site localization, while minimizing the
disadvantage of ECD (relatively long acquisition periods to achieve
good-quality mass spectra from low-abundance precursors). In
contrast to the NL ECD strategy, the targeted approach allows
(44) Keil, B. Specificity of Proteolysis; Springer-Verlag: Berlin, Germany, 1992.
(45) Olsen, J. V.; Ong, S. E.; Mann, M. Mol. Cell. Proteomics 2004, 3, 608–614.
Figure 4. Online nanoLC targeted ECD of [M + 2H]2+ ions of phosphorylated SISTVSSGS118R. Insets show observed fragments and expanded
view of $z2 and *z4, indicating the presence of phosphorylated Ser 115 and 118. ECD mass spectrum comprises 24 coadded microscans.
Table 2. Sprouty2 Phosphopeptides Identified from
Initial LC-CID MS/MS and Targeted LC-ECD MS/MS
phosphopeptide site
charge
state
localized
by
ECD?
previously
identified
site?
R.AQpSGNGSQPLLQTPR.D Ser 7 2 yes no
R.AQSGNGSpQPLLQTPR.D Ser 11 2 yes no
R.AQSGNGSQPLLQpTPR.D Thr 17 2 yes no
R.DALTQQVHVLpSLDQIR.A Ser 42 2 yes no
R.NTNEpYTEGPTVVPR.P Tyr 55 2 yes yes29
R.NTNEYpTEGPTVVPR.P Thr 56 2 yes no
R.SISTVpSSGSR.S Ser 115 2 yes yes33
R.SISTVSpSGSR.S Ser 116 2 yes no
R.SISTVSSGpSR.S Ser 118 2 yes no
R.LLGpSSFSSGPVADGIIR.V Ser138 2 yes yes33
R.LLGSpSFSSGPVADGIIR.V Ser 139 2 yes no
R.LLGSSFpSSGPVADGIIR.V Ser 141 2 yes no
R.LLGSSFSpSGPVADGIIR.V Ser 142 2 yes no
K.SELKPGELKPLpSK.E Ser 167 2 no yes33
K.VPpTVPPR.N Thr 305 2 yes no
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analysis of phosphopeptides that do not show a neutral loss, such
as phosphotyrosine peptides. The targeted approach also allows
lower abundance phosphopeptides to be selected for ECD, by
omitting more abundant phosphopeptides from the inclusion list.
In this experiment, there was a 200-fold difference between the
intensities of the most abundant phosphopeptide and the least
abundant (Supporting Information Figure 1). Targeted precursors
can be specified with a mass tolerance small enough to make false
positives unlikely, minimizing the possibility of spending time
analyzing a nonphosphorylated peptide. ECD time can therefore
be extended to maximize the information content obtained from
the targeted phosphopeptides.
Figure 3 shows ECD mass spectra obtained from [M + 2H]2+
ions of the LLGSSFSSGPVADGIIR phosphopeptide. The three
mass spectra show that four separate isoforms of this phospho-
peptide, with four distinct phosphorylation sites, are partially
resolved by the LC separation. Figure 3b shows the ECD mass
spectrum obtained at 36.5-min retention time. The fragments
observed suggest that two isoforms of the phosphopeptide are
present: one containing phosphorylation at Ser141 and one
containing phosphorylation at Ser142. The defining fragment for
the Ser141 phosphopeptide is z10• (denoted with * and enlarged
in inset). Figure 3c shows the ECD mass spectrum obtained at
retention time 37.7 min. The fragments observed suggest that the
main species is the Ser142 phosphopeptide; however, a very low
intensity z10 fragment (denoted with *) indicates the additional
presence of the Ser141 phosphopeptide in low abundance. The
complementary c ions are not observed, as is often the case for
online LC-ECD of doubly charged tryptic peptides; however, the
high mass accuracy and low noise level give added confidence to
the Ser141 z10 assignment (see Figure 3b and c inset). Figure 3d
shows the ECD mass spectrum obtained at retention time 38.7
min. The fragments observed suggest that two isoforms are
present: the Ser138 phosphopeptide and the Ser139 phosphopep-
tide. The peak at m/z 1289.65 corresponds to the z13• fragment
(denoted *) of the Ser138 phosphopeptide (see Figure 3d inset).
The lower abundance of the *z13• fragment, relative to that of the
z13• fragment from the Ser139 phosphopeptide, suggests that the
Ser139 phosphopeptide is the main species present.
An important feature of the targeted strategy is that, in cases
where different phosphorylation forms of a peptide approximately
coelute (Figure 3), both the earlier- and later-eluting forms are
sequenced because post-MS/MS dynamic exclusion is relaxed.
This would not be the case if dynamic exclusion were applied
after a single MS/MS event, as in many proteomic experiments.
Where isobaric phosphopeptides coelute, composite spectra will
be acquired. ECD mass spectra are typically acquired over a
longer period than CID spectra. High-quality ECD mass spectra
can be obtained in a few seconds; however, the time required is
dependent on the precursor abundance. Lower abundance precur-
sors require longer time to reach the target number of ions
(accumulated in the linear ion trap), prior to the rapid ECD event.
In this work, we have used up to 24 microscans, each with a
maximum permitted fill time of 1 s, in order to obtain the highest
possible quality ECD mass spectra from eluting phosphopeptides,
i.e., performing ECD throughout the elution period of a peptide.
These conditions favor the creation of composite spectra. How-
ever, interpretation of these spectra is not complicated, given that
most of the fragments are identical and that loss of modifications
from backbone fragments is not observed. Interpretation of the
corresponding linear ion trap CID mass spectra would be more
difficult, due to the potential for neutral losses of H3PO4, H2O,
and NH3 from fragments and the lower resolution of the mass
spectra. These difficulties were encountered during manual
analysis of CID MS3 spectra, where composite spectra of peptides
phosphorylated at different sites were not distinguishable from
neutral loss of H2O from unmodified serine residues.
Figure 4 shows the ECD mass spectrum obtained from [M +
2H]2+ ions of the phosphorylated SISTVSSGSR peptide. The
fragments observed and their relative intensities suggest that this
is a composite mass spectrum of three SISTVSSGSR phospho-
peptides. The predominant species is SISTVSpSGSR (pSer116).
The peaks observed at m/z 327.107 and 384.129 correspond to
the z2 and z3 fragments of SISTVSSGpSR (pSer118; denoted with
$). The peak observed at m/z 391.194 corresponds to the z4
fragment of SISTVpSSGSR (pSer115; denoted with *). From this
ECD mass spectrum, the sites of phosphorylation can be localized
to serines 115, 116, and 118. The ease of analysis of composite
ECD spectra is demonstrated in Figure 4, where fragment ion
contributions from three phosphopeptides are evident.
The complete list of identified phosphopeptides is presented
in Table 2. A total of 15 Sprouty2 phosphorylation sites have been
identified. Targeted ECD has allowed the unambiguous assign-
ment of 14 sites of phosphorylation (see Scheme 1), 11 of which
are novel. A further phosphorylation site was identified by CID
only. Mass spectra showing localization of the remaining sites are
given in the Supporting Information.
ECD fragment ion abundances from large peptides have
previously been used to quantify relative amounts of isomeric
species;46 however, this was from a direct infusion experiment.
(46) Pesavento, J. J.; Mizzen, C. A.; Kelleher, N. L. Anal. Chem. 2006, 78, 4271–
4280.
Scheme 1. Human Sprouty2 Sequence, Showing Phosphorylation Sites Identified from Initial LC-CID
MS/MS and Targeted LC ECD MS/MSa
a Phosphorylation sites are in boldface type and underlined. Accession number O43597.
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While the mass spectrum shown in Figure 4 suggests that Ser116
is the major site of phosphorylation, it should be noted that
coelution of the isomeric species may not be perfect (e.g., Figure
3) and that the yield of particular fragment ions in ECD may be
influenced by structural effects.
CONCLUSIONS
We have shown that targeted ECD is a powerful technique
for localizing sites of phosphorylation. Application of the strategy
to human Sprouty2 increased the number of phosphorylation sites
identified from 7 to 15, as well as providing increased confidence
in site localization.
A similar targeted approach could be carried out using ETD
in an ion trap instrument, as ETD has many of the same
advantages as ECD. This would similarly benefit from retention
of the labile phosphoamino acid intact, but give lower resolution
spectra.
In summary, we have applied online liquid chromatography
targeted ECD to the localization of 14 sites of Sprouty2 phospho-
rylation, 11 of which are novel. Prior to this work, only two novel
sites of phosphorylation have been identified by ECD.39,40 The
unambiguous localization of the novel phosphorylation sites
described here provides a basis for identification of the responsible
kinases, and the functional significance of, Sprouty2 phosphory-
lation events. Further quantitative experiments to this end are
ongoing in our laboratory.
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